英文字典中文字典Word104.com

中文字典辭典英文字典 a b c d e f g h i j k l m n o p q r s t u v w x y z

安裝中文字典英文字典辭典工具!

安裝中文字典英文字典辭典工具!

Recently Published | The New England Journal of Medicine
Explore this issue of The New England Journal of Medicine (Vol 0 No 0)
The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its efficacy and saf
Zongertinib in Previously Treated - The New England Journal of Medicine
Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC) Zongertinib is an oral
First-Line Camizestrant for Emerging - The New England Journal of Medicine
Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4 6) inhibitor for advanced breast cancer
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program
Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia . . .
Chemotherapy-induced thrombocytopenia (CIT) is a common complication of chemotherapy that is associated with bleeding, reduced relative dose intensity, and potentially worse outcomes No widely ava
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual Current disease-modifying therapies for multiple sclero